ArticleJournal of cell communication and signaling2026
Exosome-mediated miR-4660 delivery inhibits OPN promoted hepatoma cells aggression through targeting LGALS3BP.
Article in Journal of cell communication and signaling, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is an aggressive malignant tumor with poor prognosis due to its strong metastatic potential. Studies linked osteopontin (OPN) to increased HCC metastasis. However, the mechanisms, especially those involving exosomes, are not well elucidated. This study investigates how OPN influences HCC cells behavior via exosome mediation. A stable HCC cell line overexpressing OPN, named SMMC-OPN, was established. Co-culture experiment revealed that exosomes from SMMC-OPN cells enhanced the migration and invasion of the parental SMMC-7721 cells. RNA sequencing found the downregulation of miR-4660 in these exosomes, which targets LGALS3BP (galectin-3 binding protein), elevated in both SMMC-OPN cells and their exosomes. Treatment with SMMC-OPN exosomes resulted in an upregulation of LGALS3BP expression in SMMC-7721 cells. Notably, upon forced overexpression of miR-4660 in SMMC-OPN cells, miR-4660 was observed to be encapsulated in exosomes. Co-culture experiments demonstrated that exosomes containing miR-4660, derived from miR-4660-overexpressing SMMC-OPN cells, counter-acted the promigratory and invasive effects of SMMC-OPN exosomes on recipient SMMC-7721 cells. These findings suggest that the downregulation of miR-4660 in SMMC-OPN exosomes contributes to the enhanced metastatic potential of HCC through modulating LGALS3BP. Furthermore, miR-4660 delivery via exosomes inhibits OPN-promoted hepatoma cell aggression by targeting LGALS3BP, highlighting a potential therapeutic target against cancer metastasis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.